Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 604-609

  Xiao, Zhou Sheng ^a   Goldstein, Joyce A ^b,c   Xie, Hong Guang ^a   Blaisdell, Joyce ^b   Wang, Wei ^a   Jiang, Chang Hong ^a   Yan, Feng Xiang ^a   He, Nan ^a   Huang, Song Ling ^a   Xu, Zhen Hua ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c Hunan Medical University Changsha ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME; MEPHENYTOIN;

ALLELISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHINESE; ENZYME POLYMORPHISM; ENZYME STRUCTURE; ETHNIC DIFFERENCE; FEMALE; GENE DOSAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 8244249473     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. ALVÁN, G., BECHTEL, P., ISELIUS, L. AND GUNDERT-REMY, U.: Hydroxylation polymorphisms of debrisoquine and mephenytoin in Europeans populations. Eur. J. Clin. Pharmacol. 39: 533-537, 1990.
2. AGUNDEZ, J. A. G., MARTINEZ, C., LEDESMA, M. C., LADONA, M. G., LADERO, J. M. AND BENITEZ, J.: Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin. Pharmacol. Ther. 55: 412-417, 1994.
3. BENITEZ, J., LLERENA, A. COEALEDA, J.: Debrisoquin oxydation polymorphism in a Spanish population. Clin. Pharmacol. Ther. 44: 74-77, 1988.
4. BERTILSSON, L.: Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450(CYP)2D6 and 2C19. Clin. Pharmacokinet. 29(3): 192-209, 1995.
5. BERTILSSON, L., Lou, Y. Q., Du, Y. L., Liu, Y., KUANG, X. Y., LIAO, X-M., WANG, K. Y., REVIRIEGO, J., ISELIUS, L., AND SJO, F.: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51: 388-397, 1992.
6. BRØSEN, K., DE MORAIS, S. M. F., MEYER, U. A. AND GOLDSTEIN, J. A.: A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5: 312-317, 1995.
7. dE MORAIS, S. M. F., GOLDSTEIN, J. A., XIE, H. G., HUANG, S. L., Lu, Y. P., XIA. H., XIAO, Z. S., ILE, N. AND ZHOU, H. H.: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin. Pharmacol. Ther. 58: 404-411, 1995.
8. dE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., NAKAMURA, K., MEYER, U. A. AND GOLDSTEIN, J. A.: The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J. Bio. Chem. 269: 15419-15422, 1994a.
9. dE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., NAKAMURA, K., MEYER, U. A. AND GOLDSTEIN, J. A.: Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46: 594-958, 1994b.
10. ETLER, D. A.: Recent developments in the study of human biology in China: A review. Hum. Biol. 64567-64585, 1992.
11. FERGUSON, R. J., DE MORAIS, S. M. F., BENHAMOU, S., BOUCHARDY, C., BLAISDELL, J., WILKINSON, G. R., LINKO, P., DAYER, P. AND GOLDSTEIN, J. A.: A novel genetic defect of human CYP2C19 responsible for poor metabolism of Smephenytoin. Presented at ISSX (San Diego, CA), 1996.
12. GOLDSTEIN, J. A. AND BLAISDELL, J.: Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In Methods in Enzymology 272, Cytochrome P450, Part, ed. by E. F. Johnson and M. R. Waterman, pp. 210-218, Academic Press, New York, 1996.
13. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. AND GHANAYEM, B. L: Evidence that 2C19 is the major S-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
14. HORAI, Y., NAKANO, M., ISHIZAKI, T., ZHOU, H. H., ZHOU, B. J., LIAO, C. L. AND ZHANG, L. M.: Metoprolol and mephenytoin oxidation polymorphisms in far eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46: 198-207, 1989.
15. IYUN, A. O., LENNARD, M. S., TUCKER, G. T. AND WOODS, H. F.: Metoprulol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin. Pharmacol. Ther. 40: 387-394, 1986.
16. JURIMA-ROMET, M., GOLDSTEIN, J. A., LEBELLE, M., AUBIN, R., FOSTER. B. C., WALOP, W. AND RODE, A.: CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics 6: 329-339, 1996.
17. NAKAMURA, K., GOTO, F., RAY, W. A., MCALLISTER, C. B., JACQZ, E., WILKINSON, G. R. AND BRANCH, R. A.: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38: 402-408, 1985.
18. SAMBROOK, J., FRITSCH, E. F. AND MANIATIS. T.: Molecular Cloning: A Laboratory Manual, 2nd ed., pp. 16-19, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.
19. WANG, S. L., HUANG, J. D., LAI, M. D. AND TSAI, J. J.: Detection of CYP2C9 polymorphism based on polymerase chain reaction in Chinese. Pharmacogenetics 5: 37-42, 1995.
20. WEDLUND, P-J., SWEETMAN, B. J., MCALLISTER, C. B., BRANCH, R. A. AND WILKINSON G. R.: Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J. Chromatogr. 307: 121-127, 1984.
21. WILKINSON, G. R., GUERNGERICH, F. P. AND BRANCH, R. A.: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43: 773-780, 1989.
22. WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. AND VANDENBRANDEN, M.: Isolation and characterization of human liver cytochrome P4502C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306: 240-245, 1993.
23. XIE, H. G., HUANG, S. L. AND ZHOU, H. H.: High-performance liquid Chromatographic determination of urinary 4′-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans. J. Chromatogr. B. Biomed. Appl. 668(1): 125-131, 1995.
24. ZHANG, Y., BLOUIN, R. A., MCNAMARA, P. J., STEINMETZ, J. AND WEDLUND, P. J.: Limitation to the use of urinary S/R mephenytoin ratio in pharmacogenetic studies. Br. J. Clin. Pharmacol. 31: 350-352, 1992.